To our biosimilars advocates,
As you will see below, we have made some changes to our monthly bulletin. Our goal is to offer up timely, relevant analyses and updates in a digestible, streamlined format, and we hope this newsletter accomplishes that. You’ll find a recap of the top biosimilars stories from the previous month, along with brief commentary on upcoming opportunities or challenges for biosimilars. So, without further ado, here’s a look at what happened last month.
Biosimilar versions of Humira (adalimumab) continued to generate attention, with the news that PBMs are covering the higher-cost biosimilar but excluding the lower-list price version. This continues to shine light on PBM preferences for products with high rebates. As we’ve previously noted, it will take some time for adoption and savings from biosimilar adalimumab to kick in.